PepGen Inc
NASDAQ:PEPG
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1
7.17
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
PepGen Inc
NASDAQ:PEPG
|
387m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
386.1B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.2B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
163.5B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.6B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
86.4B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.7B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
48.4B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
PepGen Inc
Glance View
PepGen Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 31 full-time employees. The company went IPO on 2022-05-06. PepGen Inc. is a clinical-stage biotechnology company advancing the oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotides (EDOs) are designed to target the underlying causes of rare genetic diseases, such as duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The firm through its enhanced delivery oligonucleotide (EDO) platform developing a pipeline of disease-modifying peptide-conjugated oligonucleotide candidates to treat a variety of degenerative neuromuscular diseases. Its lead product candidates include PGN-EDO51 and PGN-EDODM1. Its lead product candidate PGN-EDO51, is an EDO peptide conjugated to a phosphorodiamidate morpholino oligomer (PMO) therapeutic cargo, which is developed for the treatment of DMD patients with mutations amenable to exon 51-skipping approach. The firm is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, for the treatment of DM1.